• Comorbidity of medical conditions is high for individuals with mental health diagnoses, and the potential cardiometabolic adverse effects from antipsychotic medications may be exacerbated in the presence of other risk factors.
• Guidelines for metabolic monitoring focus on individuals with prescriptions for second-generation antipsychotics (SGAs). Less attention is given to the metabolic effects of first-generation antipsychotics (FGAs).
• Despite the existence of guideline consensus recommendations for metabolic monitoring of SGAs, screening rates for glucose and lipids remain suboptimal for adults and children whose treatment services are funded by Medicaid.
What is already known about this subject
• The proportion of adults receiving glucose testing significantly increased with each successive measurement period, with 56% of adults receiving tests in 2008 and 79% in 2012. The change in the proportion of adults receiving lipid testing for each measurement period was not significant. • The proportion of youth receiving glucose testing increased significantly with each successive measurement period, with 30% of youth receiving tests in 2008 and 50% in 2012. The rate for youth receiving lipid lipid testing showed a significant increase, from 19% in 2008 to 28% in 2012.
• During the study period, there were cohort effects, including a change in the prior authorization policies for antipsychotics for those enrolled in Medicaid fee-for-service plans, as well as educational interventions developed by the public behavioral health managed care organization that targeted prescribers and members, that may have had a positive impact on rates of testing for glucose and lipids.
The U.S. Food and Drug Administration mandated a class warning for all SGAs in 2003 that required all product labeling to reference the risk of hyperglycemia and diabetes mellitus, as well as the potential for extreme hyperglycemia associated with ketoacidosis, hyperosmolar coma, or death. 5 In early 2004, the American Diabetes Association (ADA), the American Psychiatric Association (APA), the North American Association of the Study of Obesity, and the American Association of Clinical Endocrinologists issued a consensus recommendation for metabolic monitoring for individuals who have been prescribed SGAs. 6 At the time that the consensus recommendations were issued, there were limited data regarding the risks of diabetes in children and adolescents taking SGAs.
Given the shortened life expectancy of individuals with serious mental illness, chiefly due to cardiovascular disease, 10 the potential for adverse effects from psychotropic medication may be exacerbated when combined with other risk factors such as obesity, unhealthy lifestyle, and exposure to adverse childhood experiences. An association between schizophrenia and metabolic abnormalities has been noted prior to treatment with antipsychotics, and multiple studies have found that the rates of metabolic monitoring at baseline and follow-up for those prescribed SGAs remain low and fall short of recommended guidelines. [10] [11] [12] [13] Haupt et al. (2009) examined a large managed care database that measured lipid and glucose testing before and after the release of the ADA/APA guidelines and found improvements after implementation of the guidelines; however, rates remained low and those for the pediatric population were lowest.
14 A study of commercially insured patients found similar results, with only 13% of patients being given glucose and lipid tests within 6 months of beginning treatment with SGAs. 15 Raebel et al. (2014) utilized a national electronic health care database for youth newly starting SGAs and found that only 11% had been given glucose assessment between 90 days before and 30 days after first dispensing, with some variation depending on the medication used, the site, the age group, and gender. 16 FGAs are included in the data reported here because these medications are also implicated in cardiometabolic side effects. The METEOR study, a cross-sectional study that looked at the prevalence of metabolic disorders and hypertension in patients with schizophrenia, compared the prevalence of these disorders in patients being treated with FGAs and SGAs. 17 Patients were stratified by the type of antipsychotic they were receiving (FGAs or SGAs), and data collection was done at 1 point in time. The investigators found no difference in the prevalence of glycemic disorders, dyslipidemia, or metabolic syndrome for patients with schizophrenia between the group taking FGAs and the group taking SGAs. The prevalence of hypertension was higher in those treated with FGAs. The proportion of females (but not males) who were overweight or obese was higher in the group treated with SGAs. 17 A historic cohort study that compared the incidence of metabolic syndrome in first-episode patients with schizophrenia treated with either FGAs or SGAs found the rates of metabolic syndrome over the course of 3 years increased for both groups; however, the incidence was 3 times higher for those taking SGAs compared with those taking FGAs. 18 While, as a class, SGAs are recognized as increasing the risk of metabolic abnormalities, there is considerable variation in the adverse effects on metabolic indices among the various SGAs. In this cohort study, when patients being treated with clozapine and olanzapine-SGAs that are associated with a significantly negative impact on metabolic indicators-were excluded from the results, the difference between the 2 groups was no longer significant. 18 Community Care Behavioral Health Organization, a nonprofit recovery-oriented behavioral health managed care organization and part of the University of Pittsburgh Medical Center Insurance Division, identified metabolic monitoring as a quality improvement priority and began measuring the rates of metabolic monitoring in its membership in 2007. In this study, we describe trends in metabolic monitoring for adult and pediatric Medicaid recipients who have been prescribed FGAs or SGAs. We compared the rates of laboratory monitoring for glucose and lipids at 3 measurement times for adults (aged ≥ 18 years) and youth (aged ≤ 17 years). We also examined the change in monitoring rates across 3 time periods, controlling for confounding variables. We described the demographic characteristics of individuals who were least likely to receive laboratory monitoring. The difference in monitoring rates between those prescribed FSAs and SGAs was also examined across all measurement periods.
Descriptive statistics summarized the study population's characteristics (gender, age group, and race). Two dependent variables-rates of lipids test and rates of glucose test-were created to assess rates of laboratory claims during the 3 measurement periods. A dichotomous variable for lipid tests was coded "1" if an individual received a lipids test within the specified measurement times and "0" if the individual did not receive a lipids test within the specified measurement period. The glucose test outcome was a dichotomous variable coded "1" if the individual received a glucose test within the specified measurement period and "0" if the individual did not receive a glucose test within the specified measurement period. Independent variables were gender, age group, race, and antipsychotic type. Antipsychotic type was coded "1" for FGA and "0" for SGA. The FGA group included individuals prescribed only FGAs during the study period. The SGA group included those prescribed either only SGAs or FGAs and SGAs during the study period.
Differences in proportions of laboratory monitoring over the 3 time periods were assessed using separate chi square tests of association for each of the outcomes. Logistic regression models were created for each measurement period and for each outcome in order to determine characteristics of individuals who were more likely to receive laboratory tests. All statistical analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Carey, NC), with a significance level of 0.05.
■■ Results
The final study samples for the 3 measurement periods were as follows: (a) measurement period 1 (2008) (Table 3) .
The proportion of individuals receiving glucose and lipid tests was significantly different between the age groups during each measurement period ( Table 4 The results of the logistic regression models for each measurement period are displayed in Table 5 . During measurement period 1, the odds of females receiving glucose and lipid tests were 41% and 15% higher, respectively, compared with males. Females continued to be more likely to receive glucose monitoring through measurement periods 2 and 3 ( 
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males for lipid monitoring during measurement periods 2 or 3. The odds of individuals aged 17 years and younger receiving glucose tests were 59%-62% lower compared with adults aged 18 years and over for each measurement period.
Similarly, for all measurement periods, the odds of individuals aged 17 years and youger receiving lipid labs were 44%-58% lower compared with adults aged 18 years and over. While there was no significant difference between Caucasians and non-Caucasians during measurement period 1, Caucasians were about 30% less likely to receive glucose testing and about 50% less likely to receive lipid testing for measurement periods 2 and 3. During measurement period 2, individuals using FGAs were 29% more likely to receive glucose monitoring and 22% more likely to received lipid monitoring.
■■ Discussion
SGAs are widely used for a variety of psychiatric conditions, and FGAs are also still in use, largely for the treatment of schizophrenia. 19 Both types of medication carry significant risks for cardiometabolic side effects, and metabolic monitoring is suggested for people utilizing these antipsychotics. However, this monitoring is often neglected, putting these individuals at risk for life-threatening complications. We studied the demographics of those receiving laboratory monitoring over a period of 6 years to determine who was least likely to receive monitoring.
In our study, we found that rates of metabolic laboratory monitoring increased for children and adults over time. During measurement period 2, the rates were higher for glucose testing (70%) than for lipid testing (40%), a finding similar to that reported in other studies. 11, 14, 15, 20 There was a significant increase in the rate of laboratory monitoring over time in our Medicaid population, unlike the results reported in the 3-state study by . 12 While these increases were statistically significant, a noteworthy proportion of the population was still not receiving the recommended testing by the end of the study.
Females were more likely to receive testing for glucose during all measurement periods. There is limited literature addressing differences between the genders in adherence to medical recommendations. A study of adult type 2 diabetic patients found ethnic and gender differences in social support, acceptance of diabetes, quality of life, and adherence behaviors. 21 Raebel et al.'s 2014 study of pediatric patients newly begun on SGAs found that females were more likely to receive glucose testing at baseline. 16 While there was no difference between Caucasians and non-Caucasians during measurement period 1 in our study, Caucasians were less likely to receive laboratory testing in the 2 subsequent cohorts. Youth were less likely than adults to receive monitoring for glucose and lipids during the 3 measurement periods. Measurement period 2 was the only period where the likelihood of receiving glucose and lipid monitoring was affected by the type of antipsychotic drug being used. During measurement period 2, those patients prescribed FGAs were significantly more likely to receive laboratory testing than those prescribed SGAs only or SGAs with FGAs.
There are several factors that could explain the lower rates of monitoring in youth. Unlike adults, children and adolescents depend on their guardians to implement monitoring recommendations. Guardians may be reluctant to expose children and adolescents to blood draws. The likelihood of metabolic monitoring increases with age, which may make it less likely that individuals aged 17 years and under will be monitored. 15 
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individuals (aged 18-30 years) and males were less likely to be tested for glucose levels. 28 The same study found a higher likelihood of testing for lipids was associated with urban residence as well as comorbid diabetes and dyslipidemia. 28 Since African Americans are considered more at risk for metabolic abnormalities, there is a possibility that during the study period, these individuals were already being closely monitored. The population of African Americans in our study is clustered in 1 county that has access to an academic institution and a high level of care, which may explain their higher levels of testing.
Cohort effects may have had an impact on rates of metabolic monitoring during our study period. Notably, there were changes in the Pennsylvania Department of Public Welfare prior authorizations for fee-for-service programs regarding antipsychotic medication in youth. In September 2009, clinical prior authorization was required for all antipsychotic medication prescribed to children aged under 6 years, and this policy was progressively expanded to cover all youth under the age 18 years by November 2012. By January 2012, clinical prior authorization required documentation of ongoing laboratory, blood pressure, and involuntary movement disorder monitoring in children. Some managed care organizations developed prior authorization policies that were consistent with the state Medicaid fee-for-service prior authorization policies. A study have shown that children with serious or multiple psychiatric diagnoses who use health care services more intensively were more likely to receive metabolic screening. 13 A study of the determinants of metabolic testing in a Medicaid population prescribed antipsychotics found that, for children and adults, comorbid diabetes and dyslipidemia were predictors for glucose and lipid testing. 23 While the association between SGA use and type 2 diabetes in children is now known, the prevalence of these disorders in youth compared with adults has not yet been determined. Since our claims data were restricted to psychiatric diagnoses, we could not examine the impact of diabetes or lipid disorders on testing for youth or adults in our study. In the literature, there has been far less attention paid to laboratory monitoring in children using antipsychotics than monitoring in adults using antipsychotics. There are currently no pediatric guidelines for metabolic monitoring when prescribing antipsychotics in the United States. Pringsheim et al. (2011) have published guidelines specific to pediatric treatment in Canada. 24 Adults who are non-Caucasian, older, and/or who have preexisting diagnoses of diabetes, dyslipidemia, and hypertension have a greater likelihood of undergoing general glucose and lipid monitoring. 14, [25] [26] [27] ing the benefit of assigning a clinician to follow up on general physical health in individuals being treated with SGAs.
14 From a managed care perspective, we have observed that there is limited information sharing across treatment settings, which may make it difficult to track metabolic monitoring across all levels of care. Primary care providers may not have access to the laboratory studies obtained in psychiatric inpatient settings; residential, drug, and alcohol treatment settings; or in outpatient services. While electronic health records can provide such information, access to these records may be limited to a particular level of care or a specific provider or health system. Efforts to further integrate behavioral health and physical health care could include mechanisms for sharing data that would facilitate the coordination and accountability of tracking metabolic monitoring for those treated with antipsychotic medication. A reluctance to expose youth and adults to repeated testing and concerns about the cost of obtaining testing could be mitigated to some extent if there were full access for all parties to laboratory testing results obtained in different settings.
Limitations
There are some limitations to this study. First, claims data do not capture pharmacy or laboratory data on individuals receiving inpatient psychiatric services, and this study was limited to individuals in the majority of counties in a Mid-Atlantic state that were enrolled in Medicaid. Second, the monitoring rates presented here may be overestimated in reference to ADA/APA guidelines, which specify that fasting plasma glucose and lipid measures be taken at baseline and thereafter quarterly for the first year, with glucose measurements repeated annually after the first year and lipid measurements repeated every 5 years. 6 Our tests were obtained within 18-19 months rather than the 12 months recommended by the ADA/APA guidelines. We chose this time frame because it is likely that, in our population, many individuals were continuing on antipsychotics and were not new starts, in which case the 12-month monitoring interval recommended by the ADA/APA would not reflect the time frame of psychopharmacologic interventions for our population. In addition, we were aware of the barriers to obtaining blood work in a timely manner and so examined the rates of obtaining metabolic measurements within a more generous time window. Third, our focus was on laboratory testing and not on other components of metabolic monitoring, such as physical measures (i.e., body mass index, waist circumference, and blood pressure) or personal or family histories. As discussed earlier, we did not have access to physical health diagnoses claims data, so we could not examine the impact of comorbidities on the rate of laboratory testing. Finally, our use of cohorts in 3 time periods limited the possibility of generalizing the finding of an effect over time.
comparing the effects of prior authorization polices on children from Pennsylvania with those from another mid-Atlantic state enrolled in Medicaid found that prior authorization polices had a modest but statistically significant effect on antipsychotic use, decreasing use in children aged 6-12 years but having no impact on younger children. 29 Our study did not examine the impact of prior authorizations on laboratory monitoring for metabolic syndrome.
During our study period, Community Care Behavioral Health Organization implemented several educational interventions with providers. These interventions included letters to prescribers that gave details on metabolic monitoring rates for members in their geographic regions, recommendations for metabolic monitoring, and a free webinar focused on health management when prescribing antipsychotics. Provider alerts that incorporated the ADA/APA consensus guidelines and delineated expectations for providers regarding follow-up and interventions were issued in October 2011 and January 2012. 6 Members enrolled in the schizophrenia disease management program received educational outreach regarding the risk of developing metabolic syndrome provided by care managers. Members received written material recommending a discussion with their behavioral health providers and primary care doctors about blood tests and weight monitoring while on such medication.
Barriers to management of physical health conditions and consistent laboratory monitoring in individuals with serious mental illness include physician-related factors such as poor communication with the patient or difficulty maintaining communication between mental health providers and primary care providers. Physicians also do not always accept established guidelines. Service-related factors also play a role; a lack of clearly designated responsibility for recognizing and managing physical health problems and lack of integrated services can affect monitoring rates. 30 A study of Australian mental health services found that 69% of mental health center staff members were unsure about which care providers should follow up on abnormal cardiometabolic screening results. 31 A lack of communication between behavioral health care providers and physical health care providers regarding the member's treatment can result in negative health consequences associated with inadequate laboratory monitoring.
Guidelines often do not provide clarity on which provider should assume responsibility for metabolic monitoring and interventions based on the results of the monitoring. A survey of psychiatrists found that the majority were aware of the need for metabolic monitoring. 30 Psychiatrists who completed their residencies prior to the 2004 ADA/APA guidelines, and those who had a minority of patients with diagnoses of schizophrenia or bipolar disorder were more likely to agree that monitoring is the role of psychiatrists only if patients did not have primary care providers.
32, 33 Haupt et al. found that a higher number of primary care visits increased the rate of monitoring, indicat-
■■ Conclusions
The current findings suggest that, for adults and children receiving FGAs and SGAs, interventions are needed to encourage monitoring of glucose and lipid levels. This is particularly important in the pediatric population, where monitoring was lowest in our study and in the literature. As in other studies, our study found that African Americans were more likely to be monitored. However, as mentioned previously, our result may be due to a population of African Americans in a specific county where health care resources were more available than elsewhere. Managed care organizations do have a role to play in promoting metabolic monitoring. Interventions could address (a) ways in which members and their providers could work more closely to ensure that monitoring lab work is obtained; (b) enhancing access to information for patients receiving antipsychotic medications; (c) increasing integration of behavioral and physical health care; and (d) educating providers about the need for metabolic monitoring in any patient receiving antipsychotic medication. Our findings also support the need for future longitudinal investigations of laboratory monitoring.
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